If the Food & Drug Administration had been able to hand-pick the first approval under the PDUFA V review process for novel drug and biologic applications, Bayer AG/Algeta ASA’s prostate cancer treatment Xofigo would seem like a pretty good choice.
After all, FDA cleared Xofigo for marketing a full three months before the user fee deadline – a fact the agency made sure to highlight in its press...